{{Drugbox
| verifiedrevid = 449585126
| IUPAC_name = 5-allyl-5-(1,1-dimethylpropyl)pyrimidine-2,4,6(1''H'',3''H'',5''H'')-trione
| image = Nealbarbital.svg
| width = 110

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 561-83-1
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 521716
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 455089
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 25ATP958PA

<!--Chemical data-->
| C=12 | H=18 | N=2 | O=3 
| molecular_weight = 238.28 g/mol
| smiles = O=C1NC(=O)NC(=O)C1(CC(C)(C)C)C\C=C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C12H18N2O3/c1-5-6-12(7-11(2,3)4)8(15)13-10(17)14-9(12)16/h5H,1,6-7H2,2-4H3,(H2,13,14,15,16,17)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = YHKPTICJRUESOY-UHFFFAOYSA-N
| synonyms = Nealbarbital, Censedal
}}

'''Nealbarbital''' ('''Censedal''') is a [[barbiturate]] derivative developed by Aktiebolaget Pharmacia in the 1950s.<ref>US Patent 2899435</ref> It has [[sedative]] and [[hypnotic]] effects, and was used for the treatment of [[insomnia]].

== References ==
<references />

{{GABAAR PAMs}}

[[Category:Barbiturates]]
[[Category:Allyl compounds]]
[[Category:GABAA receptor positive allosteric modulators]]


{{nervous-system-drug-stub}}